LyGenesis
LyGenesis is a Pittsburgh-based clinical-stage cell therapy company developing allogeneic regenerative therapies that use a patient's own lymph nodes as bioreactors to grow functioning ectopic organs. Its lead program transplants donor hepatocytes into upper-abdominal lymph nodes via endoscopic ultrasound to treat end-stage liver disease and is in a Phase 2a clinical trial; preclinical proof-of-concept programs target thymus (aging), kidney (end-stage renal disease) and pancreas (Type 1 diabetes). LyGenesis is a laboratory and clinical-research organization, not a software vendor: it publishes no developer portal, no API documentation and no machine-readable API contract, and this profile records that absence rather than any API surface.
LyGenesis is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Regenerative Medicine, and Life Sciences.
LyGenesis’ developer surface includes support, engineering blog, and 6 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 4
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.